Preoperative Serum FGF19 in the Prognosis of Biliary Atresia
Trial Snapshot
- Phase
- Not Applicable
- Status
- Recruiting
- Enrollment
- 200
- Locations
- 1
- Primary Endpoint
- Serum total bilirubin level (umol/l)
Study Overview
Brief Summary
To investigate the role of preoperative serum FGF19 level in the prognosis of biliary atresia.
Detailed Description
Kasai portoenterostomy is currently one of the main treatment methods for biliary atresia, but about 30% of children still require liver transplantation even after receiving the surgery. Accurate prognosis will help select the most suitable treatment method for children, but there is currently a lack of effective preoperative predictive indicators. Serum FGF19 has recently been considered a possible preoperative predictive indicator for biliary atresia, but its predictive value has not been confirmed in a large sample and in Asian population, thus the investigators try to further explore the prognostic value of serum FGF19 in children with biliary atresia based on a large sample.
Study Design
- Study Type
- Observational
- Observational Model
- Case Control
- Time Perspective
- Retrospective
Eligibility Criteria
- Sex
- All
- Accepts Healthy Volunteers
- No
Inclusion Criteria
- •Samples diagnosed as biliary atresia in Children's Hospital of Fudan University
- •Samples with one-year follow-up records after surgery
- •Samples with a record of serum total bilirubin levels three months after surgery
- •Samples with preoperative serum left（volume > 500ul)
Exclusion Criteria
- Not provided
Outcomes
Primary Outcomes
Serum total bilirubin level (umol/l)
Time Frame: Three months after surgery
The difference of serum total bilirubin level will be measured with ELISA( Enzyme Linked ImmunoSorbent Assay) three months after surgery
Native liver survival (%)
Time Frame: One year after surgery
The difference of native liver survival will be measured according to the follow-up statue one year after surgery
Secondary Outcomes
No secondary outcomes reported